Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06439654 · ClinicalTrials.gov registry record · NA

Atlantic Lipid Lowering Treatment Optimization Program

A NA study of Familial Hypercholesterolemia and Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, sponsored by Atlantic Health System.

Recruiting
Registry status
NA
Development phase
250
Enrollment target
2
Study locations

NCT06439654: Recruiting NA study of Familial Hypercholesterolemia and Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, sponsored by Atlantic Health System.

NCT06439654 is a NA study of Familial Hypercholesterolemia and Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia that is actively recruiting participants, run by Atlantic Health System. The registered enrollment target is 250 participants, above the 191-participant average among 7 other Familial Hypercholesterolemia trials with a reported enrollment target (31% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06439654, a NA study of Familial Hypercholesterolemia and Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, is actively recruiting participants, sponsored by Atlantic Health System.

RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
2
Study locations

Study Summary

Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.

Primary Outcome

LDL-C \<100 mg/dL after at least six months of therapy

Interventions

  • OTHER Supportive care

Study Locations (2)

New Jersey

  • Atlantic Medical Group - Clark
  • Atlantic Medical Group - Springfield

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2024-07-01
Est. Completion 2027-12-31
Phase NA
Atlantic Health System

43 total trials

What NCT06439654 shows while recruiting

NCT06439654 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 7 other Familial Hypercholesterolemia trials with a reported enrollment target (31% higher).

The record links to 5 conditions, with Familial Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which Supportive care is the first listed.

NCT06439654 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT06439654 about?

NCT06439654 is a clinical study titled "Atlantic Lipid Lowering Treatment Optimization Program". Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup i...

What is the current status of trial NCT06439654?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2024-07-01. Estimated completion is 2027-12-31.

What conditions does trial NCT06439654 study?

This clinical trial studies the following conditions: Familial Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Apolipoprotein B 100, Familial Defective, High Density Lipoprotein Deficiency, Low-Density-Lipoid-Type Hyperlipoproteinemia.

What interventions are being tested in trial NCT06439654?

The interventions under investigation include: Supportive care (OTHER).

Who is sponsoring clinical trial NCT06439654?

This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06439654 being conducted?

This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Familial Hypercholesterolemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06439654, the US trial registry maintained by the National Library of Medicine. NCT06439654 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.